ArticleLancet regional health. Americas2026
Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.
Seungwon Lee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.